Published in Annu Rev Virol on September 01, 2014
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | NCT00625456
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors | NCT00794131
Safety Study of Modified Vaccinia Virus to Cancer | NCT00574977
A Trial of JX-594 in Refractory Colorectal Carcinoma | NCT01469611
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma | NCT00429312
Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro. J Transl Med (2016) 1.38
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology (2016) 0.87
Features of the Antitumor Effect of Vaccinia Virus Lister Strain. Viruses (2016) 0.86
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84
Cloak and Dagger: Alternative Immune Evasion and Modulation Strategies of Poxviruses. Viruses (2015) 0.84
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses (2015) 0.80
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther (2016) 0.78
Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion. Viruses (2017) 0.75
Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies. Viruses (2016) 0.75
Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity. Mol Ther Oncolytics (2016) 0.75
Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget (2016) 0.75
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun (2017) 0.75
Ribosome Profiling Reveals Translational Upregulation of Cellular Oxidative Phosphorylation mRNAs during Vaccinia Virus-Induced Host Shutoff. J Virol (2017) 0.75
The Practical Consideration of Poliovirus as an Oncolytic Virotherapy. Am J Virol (2016) 0.75
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors. Viruses (2016) 0.75
Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus. Mol Ther Methods Clin Dev (2017) 0.75
Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses. Front Oncol (2017) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 11.47
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science (2008) 5.04
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol (1994) 4.67
An antigenic difference between intracellular and extracellular rabbitpox virus. J Gen Virol (1971) 4.61
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J Gen Virol (1980) 4.24
The formation and function of extracellular enveloped vaccinia virus. J Gen Virol (2002) 4.14
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene (1983) 3.94
Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur J Cell Biol (1993) 3.46
Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. J Virol (1985) 3.44
Differences between extracellular and intracellular forms of poxvirus and their implications. Prog Med Virol (1973) 3.19
Poxvirus tropism. Nat Rev Microbiol (2005) 3.07
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol (1998) 2.97
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther (2008) 2.72
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res (2001) 2.68
Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ (2004) 2.39
Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 2.37
Vaccinia virus utilizes microtubules for movement to the cell surface. J Cell Biol (2001) 2.10
Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol (1988) 2.10
Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci U S A (1998) 1.97
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res (2005) 1.91
Extracellular enveloped vaccinia virus escapes neutralization. Virology (1996) 1.73
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2013) 1.72
Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther (2007) 1.63
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 1.54
Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis (2003) 1.54
Cell proliferative response to vaccinia virus is mediated by VGF. Virology (1988) 1.53
Vaccinia virus 4c (A26L) protein on intracellular mature virus binds to the extracellular cellular matrix laminin. J Virol (2006) 1.52
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
Immune responses to myxoma virus. Viral Immunol (2002) 1.50
Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther (2000) 1.47
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Vaccinia virus strains use distinct forms of macropinocytosis for host-cell entry. Proc Natl Acad Sci U S A (2010) 1.45
Myxomatosis in Australia and Europe: a model for emerging infectious diseases. Antiviral Res (2012) 1.41
Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 1.41
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther (2011) 1.39
Clinical development directions in oncolytic viral therapy. Cancer Gene Ther (2011) 1.37
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology (2010) 1.36
Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol (2010) 1.35
The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol (2008) 1.32
Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res (2002) 1.30
Vaccinia virus strain differences in cell attachment and entry. Virology (2009) 1.26
Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia (2009) 1.22
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation. Mol Genet Genomics (2009) 1.20
Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res (2013) 1.20
Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc Natl Acad Sci U S A (2009) 1.19
A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med (2009) 1.18
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Oncolytic vaccinia therapy of squamous cell carcinoma. Mol Cancer (2009) 1.17
Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A (2013) 1.17
Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes. Cell Microbiol (2004) 1.16
Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther (2007) 1.16
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Myxomatosis. Br Med Bull (1959) 1.14
Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine (2009) 1.14
Immunomodulatory proteins of myxoma virus. Semin Immunol (2001) 1.14
Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Mol Ther (2009) 1.13
Vaccinia virus-mediated melanin production allows MR and optoacoustic deep tissue imaging and laser-induced thermotherapy of cancer. Proc Natl Acad Sci U S A (2013) 1.13
Cancer-related anemia and recombinant human erythropoietin--an updated overview. Nat Clin Pract Oncol (2006) 1.12
Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68. PLoS One (2011) 1.11
Propagation of myxoma virus in one-day old mice. Br J Exp Pathol (1955) 1.11
Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene. Clin Cancer Res (2009) 1.10
Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol (2013) 1.09
Viruses for tumor therapy. Cell Host Microbe (2014) 1.09
The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim Biophys Acta (2007) 1.09
Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res (2008) 1.08
Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res (2010) 1.08
Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev (2010) 1.06
Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev (2010) 1.06
Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol (2007) 1.06
Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant (2012) 1.06
Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc (2006) 1.06
Poxvirus cell entry: how many proteins does it take? Viruses (2012) 1.05
Recent clinical experience with oncolytic viruses. Curr Pharm Biotechnol (2012) 1.04
Oncolytic vaccinia virus for the treatment of cancer. Expert Opin Biol Ther (2011) 1.04
Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts. Clin Cancer Res (2012) 1.04
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics. Microbes Infect (2010) 1.03
Apoptotic mimicry: phosphatidylserine-mediated macropinocytosis of vaccinia virus. Ann N Y Acad Sci (2010) 1.00
Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther (2012) 1.00
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis (2014) 0.98
The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene (2010) 0.98
A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol (2014) 0.97
Novel therapy for anaplastic thyroid carcinoma cells using an oncolytic vaccinia virus carrying the human sodium iodide symporter. Surgery (2011) 0.97
Erythropoietin in cancer patients. Annu Rev Med (2009) 0.97
Advances in the development of cancer immunotherapies. Trends Immunol (2012) 0.96